| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 65 | 2025 | 810 | 10.880 |
Why?
|
| Down Syndrome | 26 | 2025 | 231 | 6.950 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 146 | 2.770 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2025 | 92 | 2.440 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2023 | 567 | 2.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 1354 | 1.650 |
Why?
|
| Leukemia | 6 | 2023 | 379 | 1.400 |
Why?
|
| Methotrexate | 11 | 2025 | 354 | 1.370 |
Why?
|
| Child | 90 | 2025 | 25816 | 1.190 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2025 | 197 | 1.110 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 43 | 0.920 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1315 | 0.920 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 32 | 0.910 |
Why?
|
| Disease-Free Survival | 16 | 2024 | 972 | 0.890 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 2 | 0.850 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 44 | 0.830 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 125 | 0.830 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 63 | 0.830 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 1851 | 0.810 |
Why?
|
| Prognosis | 26 | 2024 | 5081 | 0.780 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 134 | 0.770 |
Why?
|
| Child, Preschool | 41 | 2025 | 14818 | 0.770 |
Why?
|
| Humans | 114 | 2025 | 134032 | 0.760 |
Why?
|
| Penetrance | 1 | 2020 | 111 | 0.670 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1187 | 0.650 |
Why?
|
| Lymphoma | 1 | 2023 | 335 | 0.640 |
Why?
|
| Integrases | 1 | 2020 | 163 | 0.630 |
Why?
|
| Receptors, Cytokine | 4 | 2024 | 69 | 0.630 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 178 | 0.630 |
Why?
|
| Infant | 30 | 2024 | 13181 | 0.620 |
Why?
|
| Adolescent | 37 | 2025 | 20581 | 0.600 |
Why?
|
| Mycoses | 2 | 2021 | 118 | 0.580 |
Why?
|
| Gene Rearrangement | 4 | 2024 | 331 | 0.550 |
Why?
|
| Salvage Therapy | 1 | 2019 | 202 | 0.540 |
Why?
|
| Acute Disease | 8 | 2023 | 1191 | 0.510 |
Why?
|
| Male | 59 | 2025 | 66022 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 824 | 0.490 |
Why?
|
| Young Adult | 21 | 2025 | 9912 | 0.480 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 549 | 0.470 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 132 | 0.460 |
Why?
|
| Female | 58 | 2025 | 71818 | 0.460 |
Why?
|
| Recurrence | 9 | 2024 | 1471 | 0.450 |
Why?
|
| Remission Induction | 2 | 2012 | 310 | 0.450 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1870 | 0.450 |
Why?
|
| Self Report | 1 | 2017 | 553 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 2936 | 0.420 |
Why?
|
| Transcription Factors | 3 | 2020 | 2728 | 0.420 |
Why?
|
| Mutation | 9 | 2023 | 6304 | 0.410 |
Why?
|
| Steroids | 1 | 2013 | 213 | 0.380 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1919 | 0.380 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 277 | 0.370 |
Why?
|
| Bacterial Infections | 1 | 2014 | 327 | 0.360 |
Why?
|
| Gene Deletion | 3 | 2021 | 810 | 0.350 |
Why?
|
| Treatment Failure | 1 | 2012 | 367 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3486 | 0.350 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 626 | 0.340 |
Why?
|
| DNA Methylation | 3 | 2021 | 1146 | 0.340 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2557 | 0.330 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 250 | 0.330 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 5 | 0.310 |
Why?
|
| Genomics | 5 | 2024 | 1674 | 0.310 |
Why?
|
| Dasatinib | 2 | 2020 | 50 | 0.310 |
Why?
|
| Metabolome | 2 | 2021 | 312 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 397 | 0.280 |
Why?
|
| Point Mutation | 1 | 2008 | 361 | 0.270 |
Why?
|
| Histones | 1 | 2011 | 571 | 0.270 |
Why?
|
| Residence Characteristics | 2 | 2020 | 293 | 0.270 |
Why?
|
| Metabolomics | 2 | 2021 | 458 | 0.260 |
Why?
|
| Neoplasms | 5 | 2024 | 3030 | 0.260 |
Why?
|
| Mice | 12 | 2025 | 19030 | 0.240 |
Why?
|
| Nondisjunction, Genetic | 1 | 2025 | 22 | 0.240 |
Why?
|
| Acrylamides | 1 | 2025 | 25 | 0.240 |
Why?
|
| Crossing Over, Genetic | 1 | 2025 | 54 | 0.240 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2025 | 21 | 0.240 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 67 | 0.240 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 294 | 0.240 |
Why?
|
| Leukapheresis | 1 | 2025 | 14 | 0.240 |
Why?
|
| Osteosarcoma | 1 | 2008 | 264 | 0.230 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Trisomy | 1 | 2025 | 112 | 0.230 |
Why?
|
| Microfluidics | 1 | 2025 | 28 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 37 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2024 | 13050 | 0.230 |
Why?
|
| Genotype | 6 | 2021 | 2806 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2024 | 746 | 0.230 |
Why?
|
| Exome | 3 | 2022 | 1068 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.220 |
Why?
|
| Animals | 16 | 2025 | 36524 | 0.220 |
Why?
|
| Mercaptopurine | 3 | 2019 | 72 | 0.220 |
Why?
|
| Survival Rate | 7 | 2021 | 2218 | 0.220 |
Why?
|
| Retrospective Studies | 15 | 2024 | 17507 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 51 | 0.220 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3660 | 0.210 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 15 | 0.210 |
Why?
|
| Constipation | 1 | 2024 | 126 | 0.210 |
Why?
|
| Piperidines | 1 | 2025 | 240 | 0.210 |
Why?
|
| Risk Factors | 10 | 2025 | 11162 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 128 | 0.210 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 49 | 0.200 |
Why?
|
| Bone Marrow | 2 | 2022 | 336 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 447 | 0.200 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5475 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 141 | 0.190 |
Why?
|
| Immunoglobulins | 1 | 2023 | 174 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 2174 | 0.190 |
Why?
|
| Gene Frequency | 2 | 2021 | 777 | 0.190 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 82 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 360 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 149 | 0.180 |
Why?
|
| Adult | 14 | 2025 | 31958 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3781 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 177 | 0.180 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 27 | 0.180 |
Why?
|
| Alleles | 3 | 2021 | 1710 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 116 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 747 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 59 | 0.170 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 11 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 171 | 0.170 |
Why?
|
| Leukocyte Count | 3 | 2025 | 259 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 521 | 0.170 |
Why?
|
| Electronic Health Records | 2 | 2024 | 796 | 0.170 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 18 | 0.160 |
Why?
|
| Incidence | 6 | 2024 | 3415 | 0.160 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 75 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 48 | 0.160 |
Why?
|
| Software | 1 | 2024 | 735 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 82 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 20 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 317 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 285 | 0.150 |
Why?
|
| Karyotyping | 4 | 2015 | 324 | 0.150 |
Why?
|
| Cytokines | 1 | 2025 | 1400 | 0.150 |
Why?
|
| Social Class | 1 | 2020 | 210 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 561 | 0.150 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 29 | 0.150 |
Why?
|
| Diploidy | 2 | 2008 | 39 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2021 | 398 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 197 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1488 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 329 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2021 | 821 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 70 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8599 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2020 | 193 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 696 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2019 | 154 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2019 | 113 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 101 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 249 | 0.140 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 61 | 0.130 |
Why?
|
| Registries | 2 | 2022 | 1576 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 920 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 2041 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 717 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 563 | 0.130 |
Why?
|
| Genome, Human | 2 | 2021 | 1348 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1155 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2020 | 579 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 119 | 0.120 |
Why?
|
| Base Sequence | 2 | 2011 | 3177 | 0.120 |
Why?
|
| Cell Line | 3 | 2013 | 2858 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2021 | 871 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 36 | 0.120 |
Why?
|
| Risk | 2 | 2023 | 835 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 704 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 772 | 0.120 |
Why?
|
| Smad Proteins | 1 | 2015 | 43 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2024 | 3732 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 345 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 793 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 275 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 807 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1940 | 0.110 |
Why?
|
| Biomarkers | 2 | 2021 | 3432 | 0.110 |
Why?
|
| Dexamethasone | 3 | 2021 | 281 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1680 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2024 | 5206 | 0.110 |
Why?
|
| Texas | 5 | 2022 | 3713 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 1145 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 407 | 0.110 |
Why?
|
| Dendritic Cells | 2 | 2013 | 447 | 0.100 |
Why?
|
| Cytosol | 1 | 2013 | 168 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2025 | 1878 | 0.100 |
Why?
|
| Age Factors | 3 | 2021 | 2994 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 355 | 0.100 |
Why?
|
| Electronics | 2 | 2023 | 46 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 952 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 36 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 486 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 577 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 444 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 680 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 170 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 358 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 1012 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 147 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 62 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 286 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 459 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 429 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 796 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2019 | 342 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 433 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 316 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 672 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 311 | 0.080 |
Why?
|
| Nitriles | 2 | 2024 | 155 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 204 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1310 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 288 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 54 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 298 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 48 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1597 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 100 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 1106 | 0.080 |
Why?
|
| Vincristine | 2 | 2021 | 196 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 707 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 619 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 545 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 255 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 69 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 837 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2024 | 417 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 649 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 357 | 0.070 |
Why?
|
| Gene Editing | 2 | 2021 | 213 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 806 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 666 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 1338 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 632 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 890 | 0.060 |
Why?
|
| Meiosis | 1 | 2025 | 117 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2793 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 99 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 48 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 14 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4867 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1387 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1627 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2025 | 4927 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 234 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1814 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 1909 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2195 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2008 | 922 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 196 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 223 | 0.050 |
Why?
|
| France | 1 | 2023 | 89 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 27 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 10 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 33 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 181 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 246 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1834 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2299 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 709 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 486 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1071 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1310 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 340 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2444 | 0.050 |
Why?
|
| Entropy | 1 | 2021 | 29 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2021 | 38 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 7 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 49 | 0.040 |
Why?
|
| Transcriptome | 2 | 2019 | 1137 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 40 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 33 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 33 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 377 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 988 | 0.040 |
Why?
|
| United States | 3 | 2021 | 11752 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 253 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1720 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 136 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 519 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 604 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 139 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 58 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 44 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 111 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 20 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 119 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 890 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 246 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 300 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 148 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 236 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 4006 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 118 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 834 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 306 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 556 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 791 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 120 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 480 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 369 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 75 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 164 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4554 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 21 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1095 | 0.040 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 22 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 391 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 281 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 609 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3890 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 187 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 159 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 611 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 63 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 645 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 21 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1440 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 6601 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 42 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 620 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 187 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 687 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 403 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 425 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 320 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1421 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 887 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 318 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1255 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 912 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 727 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 894 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 615 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 296 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 174 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 140 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2157 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 135 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 564 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1737 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 35 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 100 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 27 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 847 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 70 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 47 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 19 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 538 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 756 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1761 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 2127 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 83 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 133 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 225 | 0.020 |
Why?
|
| Epilepsy | 1 | 2020 | 893 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 151 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 1620 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 777 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1711 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 719 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 867 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1737 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 690 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4801 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 538 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2536 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 820 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1214 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1492 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2169 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 523 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1854 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1022 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3043 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2092 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 3181 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 29393 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 21750 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 737 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2664 | 0.010 |
Why?
|